Lack of prognostic significance of HER-2/neu in early epithelial ovarian cancer.
A total of 74 patients with apparent early stage epithelial ovarian cancer who underwent exploratory laparotomy at King Chulalongkorn Memorial Hospital or other hospitals and were referred for further treatment, were evaluated. Formalin fixed paraffin-embedded ovarian tissue specimens were collected and immuno-stained with HER-2/neu antibodies for comparison with clinicopathologic data after median follow up of 46 months (range 3 - 83 months). The prevalence of HER-2/neu overexpression in these patients was 10.2%. No significant correlation between HER-2/neu overexpression and clinicopathological parameters (stage, ascites, capsular rupture, capsular adherence, histological subtype and histological grade) was found. Disease free survival and overall survival did not statistically differ between those with lesions positive or negative for HER-2/neu overexpression.
Sueblinvong
Thanasak
T
sthanasak@yahoo.com
Manchana
Tarinee
T
Khemapech
Nipon
N
Triratanachat
Surang
S
Termrungruanglert
Wichai
W
Tresukosol
Damrong
D
D018262:Adenocarcinoma, Clear Cell / Q000378:metabolism / Q000556:secondary; D002288:Adenocarcinoma, Mucinous / Q000378:metabolism / Q000556:secondary; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism*; D018269:Carcinoma, Endometrioid / Q000378:metabolism / Q000556:secondary; D002462:Cell Membrane / Q000378:metabolism / Q000473:pathology; D018284:Cystadenocarcinoma, Serous / Q000378:metabolism / Q000556:secondary; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000378:metabolism; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000378:metabolism*; D016612:Paraffin Embedding; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D012189:Retrospective Studies
D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases